Palvella Therapeutics, Inc. (PVLA)
PVLA Stock Price Chart
Explore Palvella Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze PVLA price movements and trends.
PVLA Company Profile
Discover essential business fundamentals and corporate details for Palvella Therapeutics, Inc. (PVLA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Jan 2015
Employees
14.00
Website
https://palvellatx.comCEO
Wesley H. Kaupinen
Description
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
PVLA Financial Timeline
Browse a chronological timeline of Palvella Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.84.
Earnings released on 14 Aug 2025
EPS came in at -$0.86 falling short of the estimated -$0.78 by -10.26%.
Earnings released on 15 May 2025
EPS came in at -$0.74 surpassing the estimated -$3.40 by +78.24%.
Earnings released on 31 Mar 2025
EPS came in at $4.00 surpassing the estimated -$0.39 by +1.13K%.
Earnings released on 13 Nov 2024
EPS came in at -$2.19 falling short of the estimated -$0.55 by -301.83%.
Earnings released on 14 Aug 2024
EPS came in at -$2.76 falling short of the estimated -$2.40 by -15.00%.
Earnings released on 16 May 2024
EPS came in at -$2.00 surpassing the estimated -$4.80 by +58.33%.
Stock split effective on 23 Apr 2024
Shares were split 1 : 80 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Mar 2024
EPS came in at -$3.71 surpassing the estimated -$9.60 by +61.40%, while revenue for the quarter reached $1.30M , missing expectations by -42.11%.
Earnings released on 15 Nov 2023
EPS came in at -$8.70 surpassing the estimated -$8.80 by +1.15%, while revenue for the quarter reached $19.52M , beating expectations by +152.07%.
Earnings released on 11 Aug 2023
EPS came in at $3.62 surpassing the estimated -$12.54 by +128.88%, while revenue for the quarter reached $20.06M , beating expectations by +399.00%.
Earnings released on 11 May 2023
EPS came in at -$1.17 surpassing the estimated -$14.68 by +91.99%, while revenue for the quarter reached $1.94M , missing expectations by -28.77%.
PVLA Stock Performance
Access detailed PVLA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.